Long-term outcomes of Guillain-Barré syndrome possibly associated with Zika virus infection

Diana M. Walteros1, Jesus Soares2, Ashley R. Styczynski3, Joseph Y. Abrams2, Jose I. Galindo-Buitrago4, Jorge Acosta-Reyes4, Elsa Bravo-Ribero5, Zuleima E. Arteta6, Alma Solano-Sanchez5, Franklyn E. Prieto1, Maritza Gonzalez-Duarte1, Edgar Navarro-Lechuga6, Jorge L. Salinas6, Ermias D. Belay2, Lawrence B. Schonberger2, Inger K. Damon2, Martha L. Ospina1, James J. Sejvar2*

1 Instituto Nacional de Salud, Bogota, Colombia, 2 Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 3 Stanford University Department of Infectious Diseases, Palo Alto, California, United States of America, 4 TEPHINET - Institute for Global Health, Decatur, Georgia, United States of America, 5 Universidad del Norte, Barranquilla, Colombia, 6 Secretaría de Salud de Barranquilla, Barranquilla, Colombia, 7 University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States of America

* zea3@cdc.gov

Abstract

Background
This prospective cohort investigation analyzed the long-term functional and neurologic outcomes of patients with Zika virus-associated Guillain-Barré syndrome (GBS) in Barranquilla, Colombia.

Methods
Thirty-four Zika virus-associated GBS cases were assessed a median of 17 months following acute GBS illness. We assessed demographics, results of Overall Disability Sum Scores (ODSS), Hughes Disability Score (HDS), Zung Depression Scale (ZDS), and Health Related Quality of Life (HRQL) questionnaires; and compared outcomes indices with a normative sample of neighborhood-selected control subjects in Barranquilla without GBS.

Results
Median age at time of acute neurologic onset was 49 years (range, 10–80); 17 (50%) were male. No deaths occurred. At long-term follow-up, 25 (73%) patients had a HDS 0–1, indicating complete / near complete recovery. Among the group, HDS (mean 1.4, range 0–4), ODSS (mean 1.9, range 0–9) and ZDS score (mean 34.4, range 20–56) indicated mild / moderate ongoing disability. Adjusting for age and sex, Zika virus-associated GBS cases were similar to a population comparison group (n = 368) in Barranquilla without GBS in terms of prevalence of physical or mental health complaints, though GBS patients were more likely to have an ODSS of ≥ 1 (OR 8.8, 95% CI 3.2–24.5) and to suffer from moderate / moderate-severe depression (OR 3.89, 95% CI 1.23–11.17) than the comparison group.
Conclusions

Long-term outcomes of Zika virus-associated GBS are consistent with those associated with other antecedent antigenic stimuli in terms of mortality and ongoing long-term morbidity, as published in the literature. Persons with Zika virus-associated GBS more frequently reported disability and depression after approximately one year compared with those without GBS.

Introduction

Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy resulting in limb and cranial nerve weakness, often with respiratory compromise, with variable consequent limitations on physical function. The disease is commonly precipitated by an infection, and infectious agents previously associated with GBS include Campylobacter jejuni, Mycoplasma pneumoniae, cytomegalovirus, and Epstein-Barr virus.[1] The incidence of GBS worldwide ranges from 0.81 to 1.89 cases per 100,000 person–years,[2] but these estimates may vary depending on robustness of surveillance and the regional prevalence of etiologic triggers. Most recently, the increased incidence of GBS in regions where outbreaks of Zika virus (ZIKV) have occurred epidemiologically suggests that ZIKV is a new infectious agent associated with GBS.[3–7]

GBS is heterogeneous in severity of neurological deficits and prognosis.[8] People with GBS usually experience their most significant weakness within two to four weeks after symptoms begin, and as the disease progresses, weakness can evolve into paralysis. In some cases, the disease can result in neuromuscular respiratory failure leading to the need for ventilatory support. Despite effective therapies, such as intravenous immunoglobulin (IVIG) and plasma exchange, death or disability can occur. Death has been reported to range from 1–18%,[9] and that about 20%-35% of hospitalized patients experience long-term disability.[10, 11]

Studies of GBS outcomes suggest that by one year from onset of the neurologic signs, 62%-92% of patients achieve complete / near complete recovery, regaining the ability to perform manual work and other motor activities.[10–14] However, due to limitations in the physical condition of GBS patients, even years after the acute phase of the disease, their health related quality of life might be compromised by symptoms of fatigue, pain, anxiety, and depression.[15, 16] In addition, most outcomes assessments have been conducted in North America and Europe, where aggressive intervention and rehabilitation services may influence ultimate outcome. Less is known about the eventual outcomes of GBS in resource-limited settings.

Although the prognosis for recovery in GBS patients is generally favorable, with most patients experiencing complete recovery or only minor sequelae, anecdotal reports have suggested that ZIKV-associated GBS has a worse outcome or prognosis than that seen with GBS associated with other antecedent antigenic triggers. However, the long-term neurological and functional outcomes of patients affected by GBS during the ZIKV outbreaks have undergone limited prospective systematic assessments.[6] Therefore, we aimed to analyze the long-term functional and neurologic outcomes of GBS patients associated with ZIKV in Barranquilla, Colombia, an area that experienced a significant outbreak of ZIKV infections and a high incidence of GBS.
Methods

Ethics statement
The human subjects review committee at the U.S. Centers for Disease Control and Prevention (CDC) determined this investigation to be public health emergency response and not research, and as such did not require full Institutional Review Board approval. The Colombian National Institute of Health relied on CDC’s determination. All subjects provided written informed consent prior to investigation participation.

Confirmation of GBS status and clinical description

The enrollment process of the patients with GBS for this investigation was previously published by Salinas et al. in 2017.[3] Briefly, in April 2016, the authors searched for case-patients fulfilling Brighton Collaboration criteria for GBS,[17] who were Barranquilla residents according to phone numbers and their residency as listed in their medical record. Forty patients meeting Brighton case definition criteria 1–3 for GBS[18] were included in the investigation, and the demographics and clinical characteristics of these patients were described.[3] All GBS case-patients had laboratory-confirmed or clinically-suspected ZIKV infection; laboratory confirmation by plaque-reduction neutralization testing (PRNT) demonstrated that 5 / 40 had evidence of a previous dengue infection, 21 / 40 had evidence of a previous ZIKV or dengue virus infection, and 1 / 40 had evidence of a recent ZIKV infection. A first assessment standardized questionnaire was used to interview the GBS patients to obtain demographic information and antecedent symptoms within a two-month period before the onset of neurological signs/symptoms. Serum samples were collected to perform serologic testing for ZIKV.

In the present study, a follow-up survey to determine long-term disability was conducted between May and July 2017. We re-contacted 34 of the previous 40 patients; four had moved out of Barranquilla, one refused participation, and one was unable to be located. The 34 patients were included in this follow-up investigation (Fig 1).

The patients at follow-up were administered a structured in-person interview to assess functional disabilities, including the Hughes Disability Scale[19] and the Modified Rankin...
We also estimated the levels of depression using the Zung Self-Rating Depression Scale; health-related quality of life (HRQoL) was assessed using the CDC Healthy Days questionnaire. A neurologist performed a physical and neurologic exam, which included the determination of each patient’s Overall Disability Sum Score (ODSS).

Because there were no first assessment data for certain indices (ODSS, Zung Depression Scale, HRQoL), we wanted to compare these results from GBS patients to a referent population in order to determine whether there were differences between the GBS group and the general population of Barranquilla. A population sample used for a prior study of health-related quality of life in Barranquilla (Acosta et al., unpublished data) was used for the comparison population. Briefly, 368 non-hospitalized adults ≥ 18 years old who were living at home and were without neurological symptoms were sampled from four geographic regions of the city of Barranquilla in May 2017. The comparison population was selected to be similar in age group and residence to the GBS patient population. The comparison population was assessed for demographic information and measurements of disability, depression and health-related quality of life.

Statistical analyses

Descriptive statistics were calculated for demographic, clinical, disability, depression, and health-related quality of life data at time of follow up.

Odds ratios were used to compare prevalence of disabilities at the baseline and follow-up surveys. For comparison of cases to the non-hospitalized comparison group, multivariable logistic regression was utilized for questions related to self-reported health status, the health related quality of life, the ODSS, and the Zung scale, adjusting for age and sex. For analyses on individual Zung items, which were answered on a scale of 1 (most normal) to 4 (most depressed), we used proportional odds logistic regression, adjusting for age and sex. For Zung index comparisons, in order to avoid excluding patients who were missing answers for a small number of items, we utilized multiple imputation based on available Zung item answers for each patient using ordered logit modeling from the R package “mice” (multiple imputation by chained equations) [25].

Demographic differences between the case and comparison groups were assessed by the Mann Whitney U test and the chi-squared test with Yates continuity correction.

All data were analyzed using R version 3.3.3 (The R Foundation for Statistical Computing, 2017).

Results

Characteristics of GBS cases at baseline and follow-up

The median time from neurologic symptom onset to first assessment survey for the 34 GBS patients was three months (IQR: 2–3 months; range: 0.9–6).[3] In the present study, long-term follow-up data were collected a median of 17 months after symptom onset (IQR: 16–17 months; range: 14–20). The demographics, clinical characteristics, and treatment of these GBS patients at the time of first assessment in 2016 are reproduced in Table 1.

Fifty percent (17/34) of the cohort were male, and the median age at onset of acute GBS was 49 years (IQR 35.0–60.75). The median time between prodromal illness and onset of neurological symptoms was seven days (IQR 2–15). All patients (100%) were admitted to the hospital and median duration of hospitalization was 14.5 days (IQR 9.25–28.75). Sixty-eight percent were admitted to intensive care unit/critical care unit (ICU/CCU) and seven patients (21%) received mechanical ventilation. Treatment received by GBS patients included intravenous immunoglobulin (91%), steroids (38%), and plasma exchange (18%). During acute GBS illness
at clinical nadir, 41% of patients were not able to walk without assistance, and 31% were unable to walk at all.

Ninety-one percent of patients went to rehabilitation services after hospital discharge for physical therapy, and 12% received home health therapy (Table 2).

The neurologic signs demonstrated by the GBS patients at baseline and follow up are summarized in Table 3.

At baseline 94% of these patients reported leg weakness and 91% reported arm weakness. The proportion of patients reporting face weakness, leg numbness, and arm numbness was 53%, 77%, and 68%, respectively. At follow-up the proportion of patients reporting neurologic symptoms decreased significantly for all five domains evaluated. Aside from a single patient who reported face weakness at follow-up but not at baseline, all individuals who reported any of these neurologic signs at follow-up had previously reported those signs at baseline.

The results of neurologic evaluation using the Hughes score at baseline and follow-up are represented in Fig 2.

Ongoing issues with health-related quality of life were captured in the follow-up survey (Fig 3).

Table 1. Descriptive statistics for 34 GBS patients, Barranquilla, Colombia.

|                          |       |
|--------------------------|-------|
| Sex                      |       |
| Female                   | 17 (50%) |
| Male                     | 17 (50%) |
| Age at onset             |       |
| Median (IQR)             | 49 (35, 60.75) |
| Range                    | (10, 80) |
| Days in hospital         |       |
| Median (IQR)             | 14.5 (9.25, 28.75) |
| Range                    | (4, 60) |
| Admitted to the ICU/CCU  |       |
| Yes                      | 23 (68%) |
| No                       | 11 (32%) |
| Received mechanical ventilation |   |
| Yes                      | 7 (21%) |
| No                       | 27 (79%) |
| Received intravenous immunoglobulin |   |
| Yes                      | 31 (91%) |
| No                       | 3 (9%) |
| Received steroids        |       |
| Yes                      | 13 (38%) |
| No                       | 21 (62%) |
| Received plasma exchange |       |
| Yes                      | 6 (18%) |
| No                       | 28 (82%) |
| Unable to walk without assistance (at clinical nadir) | |
| Yes                      | 13 (41%) |
| No                       | 19 (59%) |
| Unable to walk at all (at clinical nadir) | |
| Yes                      | 10 (31%) |
| No                       | 22 (69%) |

https://doi.org/10.1371/journal.pone.0220049.t001
Incidence of GBS in Barranquilla during the study period was substantially higher than incidence reported in 13 previous studies of GBS incidence conducted in Europe and North America[2] (Fig 4), and comparable to incidence of ZIKV-associated GBS in other areas of the Caribbean and South America. [4, 26]

Comparison of cases with normal Barranquilla sample population at follow-up

The demographic characteristics of the non-GBS comparison population is shown in Table 4. The non-GBS comparison group had a median age of 44.5 years and an IQR of 30 to 59 years (as compared to a median of 49 years and an IQR of 35 to 60.75 years for cases); the difference in age between the comparison population and cases was not statistically significant (p = 0.33). The proportion of the comparison group that was male (56%) was not significantly different from the proportion of cases that was male (50%) (p = 0.65).

Fig 5 demonstrates comparative data (odds ratios) between cases and comparison group on the various indices assessed.

Table 5 demonstrates these results in tabular form.

Discussion

Our investigation evaluated the long-term outcomes of ZIKV-associated GBS at 14–20 months after initial GBS illness. Our findings suggest that the long-term morbidity in ZIKV-associated GBS are consistent with that described in GBS literature for GBS associated with other antecedent antigenic stimuli. The proportion of patients requiring mechanical ventilation during...
hospitalization (20%) is consistent with estimations in other GBS assessments.[27–30] The proportion of patients experiencing complete or near-complete recovery at time of hospital discharge (Hughes disability score 0–1, 73%) is also consistent with previously published values; review articles summarizing the long-term outcomes of GBS due to other antecedent triggers have consistently provided such estimates.[31–34] In terms of long-term outcomes, nearly all patients continued to experience improvement in limb and cranial nerve weakness during the intervening 14–20 months, as evidenced by improving Hughes scores and proportional improvement in limb weakness, suggesting that improvement from ZIKV-associated GBS may continue for months following hospital discharge. Other long-term assessments of recovery following GBS have found similar evidence of ongoing improvement in strength and function for months or years following acute GBS illness.[10–12, 35, 36]

At long-term assessment, we found that GBS patients were more likely than the comparison population group to have ongoing disability as evidenced by an ODSS of 1 or greater as assessed by neurologic examination; this is not necessarily a surprising finding, but does demonstrate ongoing morbidity in the GBS group. GBS patients were also more likely to experience moderate or moderate-severe depression than the general population of Barranquilla,

Fig 2. Comparison of Hughes score at baseline and follow-up for 34 GBS patients, Barranquilla, Colombia. The vertical lines connect each patient’s Hughes scores at baseline and follow-up. Eighteen (52%) cases had a Hughes score of 0–1 at baseline and 25 (74%) of cases had a Hughes score of 0–1 at follow-up. Eighteen of the cases had a lower Hughes score at follow-up compared to baseline, 14 had the same Hughes score, and two had a higher Hughes score at follow-up (shown in red). Hughes scores were significantly lower at follow-up (paired T test p-value: 0.0008).

https://doi.org/10.1371/journal.pone.0220049.g002
conceivably due to a reactive depression after experiencing a disabling illness. However, on quality of life indices assessing the occurrence of physical or mental difficulties or functional problems due to physical or mental difficulties in the 30 days prior to interview, there were no substantial differences between the GBS patients and the comparison population group. This suggests that, despite ongoing weakness and depression in some, overall quality of life indices did not differ significantly between those with and without GBS in this population.

The proportion of patients with complete or near-complete recovery at follow-up (Hughes score 0–1, n = 25, 73%) is similar to other investigations assessing the outcomes of Zika-associated GBS.[6, 37] However, recovery was not universal, and nine patients continued to experience function-limiting sequelae at follow-up. These sequelae were predominantly in the domains of ongoing weakness and depression.

Other investigations assessing long-term (one year or greater) outcomes of GBS have had variable findings. Cheng et al. determined that 40% of 60 GBS patients remained with physical and functional sequelae at one year.[38] Alternately, another retrospective investigation into the long-term outcomes of ZIKV-associated GBS determined that 80% of 15 GBS patients experienced good recovery at one year, with 13% having physical / functional sequelae.[37] Our investigation demonstrated recovery patterns consistent with that of other published data assessing GBS attributable to etiologies other than ZIKV.[39, 40]

As previously demonstrated, incidence of GBS increased with age.[2] However, the overall incidence in nearly every age group was far in excess of what would normally be expected, particularly in persons over age 60. A similar phenomenon was witnessed in Brazil, where age-specific incidence from a ZIKV-associated GBS case-control investigation demonstrated substantially higher incidence rates among all age groups and particularly in persons aged 60 or older.[4] The reason for the dramatic increased incidence among older age groups in ZIKV-associated GBS is unclear.

Our investigation has limitations. Not all cases were laboratory-confirmed ZIKV infections; a proportion of cases were diagnosed using clinical criteria; thus, misclassification of some
cases may be possible. However, all cases met clinical compatibility criteria for ZIKV infection as published elsewhere.[41] The fact that the first assessment was conducted up to 6 months following onset of neurologic illness may have resulted in recall bias in some individuals. We were unable to assess risk factors or other prognostic factors associated with clinical outcomes.

Table 4. Demographic characteristics of GBS cases and sampled normal population, Barranquilla, Colombia.

| Characteristics | Cases | Comparison Group |
|-----------------|-------|------------------|
| **Sex**         |       |                  |
| Female          | 17 (50%) | 163 (44%)         |
| Male            | 17 (50%) | 205 (56%)         |
| **Age (years)** |       |                  |
| 18–24           | 4 (12%)  | 53 (14%)          |
| 25–39           | 7 (21%)  | 90 (25%)          |
| 40–54           | 10 (30%) | 119 (32%)         |
| 55–69           | 8 (24%)  | 58 (16%)          |
| > 70            | 5 (15%)  | 48 (13%)          |

https://doi.org/10.1371/journal.pone.0220049.t004

Fig 4. Incidence of GBS by midpoint of age groups, Barranquilla, Colombia, compared to previous studies. The red curve represents age-specific incidence for Barranquilla (right y-axis) and the black curves represent age-specific incidence for 13 previous studies (left y-axis). The blue curve (also left y-axis) represents a loess curve, weighted by person-years, fitted to incidence data from the previous studies. Data for previous studies from Sejvar et al. 2011.[2] While incidence generally increased with age in these previous studies, the observed association between age and incidence was even more pronounced in the Barranquilla investigation.

https://doi.org/10.1371/journal.pone.0220049.g004
which would have been a valuable asset to this investigation. However, we were able to provide robust, prospective, systematic assessments on a relatively large group of ZIKV-associated GBS cases to determine long-term outcomes, an important strength of our investigation. In addition, this study was able to compare physical, mental, and quality of life indices with a normative population. Compared to other investigations of outcomes of ZIKV-associated GBS,[6, 37] ours was a prospective investigation covering over a year of follow-up.

Conclusions

In summary, long-term outcomes of ZIKV-associated GBS are consistent with GBS presentations associated with other etiologies in terms of mortality and ongoing long-term morbidity,
as published in the literature. Additionally, long-term physical and mental status among persons with ZIKV-associated GBS after one year were similar to persons without GBS, though disability and depression were more common among GBS patients after one year. Further long-term clinical and epidemiologic assessments of ZIKV-associated GBS using larger sample sizes are needed to substantiate these findings and identify prognostic indicators for outcome.

**Acknowledgments**

The authors would like to acknowledge the valuable contributions of Teresa Hammett (Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA); Alejandra

---

**Table 5. Odds ratios comparing disability for GBS cases at follow-up with the comparison group.**

| Physical health issues                  | Case          | Comparison Group | Unadj OR (95% CI) | Adj OR (95% CI) |
|----------------------------------------|---------------|------------------|-------------------|-----------------|
| 0 days                                 | 20 (59%)      | 212 (63%)        | REF               | REF             |
| 1–10 days                              | 10 (29%)      | 72 (21%)         | 1.47 (0.66, 3.29) | 1.50 (0.64, 3.29) |
| >10 days                               | 4 (12%)       | 52 (16%)         | 0.82 (0.27, 2.49) | 0.74 (0.20, 2.17) |
| Any days w/issues                      | 14 (41%)      | 124 (37%)        | 1.20 (0.58, 2.45) | 1.16 (0.55, 2.37) |

| Mental health issues                   | Case          | Comparison Group | Unadj OR (95% CI) | Adj OR (95% CI) |
|----------------------------------------|---------------|------------------|-------------------|-----------------|
| 0 days                                 | 23 (68%)      | 252 (76%)        | REF               | REF             |
| 1–10 days                              | 4 (12%)       | 48 (14%)         | 0.91 (0.30, 2.76) | 0.92 (0.26, 2.54) |
| >10 days                               | 7 (21%)       | 33 (10%)         | 2.32 (0.93, 5.84) | 2.20 (0.81, 5.36) |
| Any days w/issues                      | 11 (32%)      | 81 (24%)         | 1.49 (0.70, 3.18) | 1.46 (0.66, 3.07) |

| Restricted activity due to health issues| Case          | Comparison Group | Unadj OR (95% CI) | Adj OR (95% CI) |
|----------------------------------------|---------------|------------------|-------------------|-----------------|
| 0 days                                 | 26 (77%)      | 257 (78%)        | REF               | REF             |
| 1–10 days                              | 3 (9%)        | 51 (16%)         | 0.58 (0.17, 1.99) | 0.57 (0.13, 1.70) |
| >10 days                               | 5 (15%)       | 21 (6%)          | 2.35 (0.82, 6.76) | 2.25 (0.68, 6.40) |
| Any days w/issues                      | 8 (24%)       | 72 (22%)         | 1.10 (0.48, 2.53) | 1.05 (0.43, 2.34) |

| Zung depression index                  | Case          | Comparison Group | Unadj OR (95% CI) | Adj OR (95% CI) |
|----------------------------------------|---------------|------------------|-------------------|-----------------|
| Normal (<50)                           | 24 (71%)      | 293 (80%)        | REF               | REF             |
| Mild depression (50–59)                | 4 (12%)       | 58 (16%)         | 0.84 (0.28, 2.52) | 0.79 (0.22, 2.17) |
| Moderate depression (60–69)            | 5 (15%)       | 14 (4%)          | 4.36 (1.45, 13.13) | 3.81 (1.10, 11.59) |
| Severe depression (70+)                | 1 (3%)        | 3 (1%)           | 4.07 (0.41, 40.63) | 4.52 (0.20, 46.78) |
| Moderate to severe depression (60+)    | 6 (18%)       | 17 (5%)          | 4.31 (1.55, 11.94) | 3.89 (1.23, 11.17) |
| Any depression (50+)                   | 10 (29%)      | 75 (20%)         | 1.63 (0.75, 3.55) | 1.48 (0.63, 3.24) |

| Zung index, emotional (12 questions)   | Case          | Comparison Group | Unadj OR (95% CI) | Adj OR (95% CI) |
|----------------------------------------|---------------|------------------|-------------------|-----------------|
| Normal (<30)                           | 24 (71%)      | 315 (86%)        | REF               | REF             |
| High (30+)                             | 10 (29%)      | 53 (14%)         | 2.48 (1.12, 5.47) | 2.31 (0.97, 5.22) |

| Zung index, physical (8 questions)     | Case          | Comparison Group | Unadj OR (95% CI) | Adj OR (95% CI) |
|----------------------------------------|---------------|------------------|-------------------|-----------------|
| Normal (<20)                           | 24 (71%)      | 279 (76%)        | REF               | REF             |
| High (20+)                             | 10 (29%)      | 89 (24%)         | 1.31 (0.60, 2.84) | 1.18 (0.51, 2.56) |

| ODSS                                   | Case          | Comparison Group | Unadj OR (95% CI) | Adj OR (95% CI) |
|----------------------------------------|---------------|------------------|-------------------|-----------------|
| Normal ODSS (0)                        | 22 (65%)      | 346 (94%)        | REF               | REF             |
| ODSS score 1–2                         | 5 (15%)       | 13 (4%)          | 6.05 (1.98, 18.50) | 6.48 (1.91, 19.42) |
| ODSS score 3+                          | 7 (21%)       | 9 (2%)           | 12.23 (4.16, 35.94) | 34.38 (7.33, 221.95) |
| Any score 1+                           | 12 (35%)      | 22 (6%)          | 8.58 (3.76, 19.57) | 10.28 (4.09, 26.09) |

All odds ratio are the relative odds of a given category as opposed to the reference (healthy) category for the cases compared to those odds for the comparison group. Adjusted odds ratios are from logistic regression controlling for sex and age. Zung scores: only 34 of 8040 (0.4%) of responses were missing, but 27 of 402 (6.7%) of individuals were missing at least one response, so multiple imputation was used to account for missing values.

https://doi.org/10.1371/journal.pone.0220049.t005
Beleño, Daniel Moreno, Diana Madariaga, and Mariana Mansur (TEPHINET, Institute for Global Health, Decatur, GA, USA), and the staff of the Health Secretary of Barranquilla, for their help and assistance on logistics, data management, and technical support on this investigation. Drs. Oswaldo Lara and Angela Ulloa for their assistance on clinical evaluation of the GBS patients.

Disclaimer

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.

Author Contributions

Conceptualization: Diana M. Walteros, Jesus Soares, Ashley R. Styczynski, Jorge Acosta-Reyes, Jorge L. Salinas, James J. Sejvar.

Data curation: Diana M. Walteros, Joseph Y. Abrams, Jose I. Galindo-Buitrago, Jorge Acosta-Reyes.

Formal analysis: Diana M. Walteros, Jesus Soares, Joseph Y. Abrams.

Funding acquisition: Inger K. Damon, James J. Sejvar.

Investigation: Diana M. Walteros, Maritza Gonzalez-Duarte, Jorge L. Salinas, Lawrence B. Schonberger, James J. Sejvar.

Methodology: Diana M. Walteros, Ashley R. Styczynski, Joseph Y. Abrams, Jose I. Galindo-Buitrago, Jorge Acosta-Reyes, Edgar Navarro-Lechuga, Jorge L. Salinas, James J. Sejvar.

Project administration: Diana M. Walteros, Jesus Soares, Elsa Bravo-Ribero, Zuleima E. Arteta, Alma Solano-Sanchez, Franklyn E. Prieto, Edgar Navarro-Lechuga, Inger K. Damon, Martha L. Ospina, James J. Sejvar.

Resources: Elsa Bravo-Ribero, Zuleima E. Arteta, Alma Solano-Sanchez, Franklyn E. Prieto, Maritza Gonzalez-Duarte, Ermias D. Belay, Martha L. Ospina, James J. Sejvar.

Supervision: Diana M. Walteros, Jesus Soares, Ashley R. Styczynski, Jose I. Galindo-Buitrago, Jorge Acosta-Reyes, Elsa Bravo-Ribero, Ermias D. Belay, Inger K. Damon, Martha L. Ospina, James J. Sejvar.

Validation: Diana M. Walteros, Joseph Y. Abrams, Jorge Acosta-Reyes, James J. Sejvar.

Writing – original draft: Diana M. Walteros, Jesus Soares, Ashley R. Styczynski, Joseph Y. Abrams, Jorge Acosta-Reyes, Maritza Gonzalez-Duarte, Edgar Navarro-Lechuga, Jorge L. Salinas, Ermias D. Belay, Lawrence B. Schonberger, Martha L. Ospina, James J. Sejvar.

Writing – review & editing: Diana M. Walteros, Jesus Soares, Ashley R. Styczynski, Joseph Y. Abrams, Jorge Acosta-Reyes, Franklyn E. Prieto, Maritza Gonzalez-Duarte, Edgar Navarro-Lechuga, Jorge L. Salinas, Ermias D. Belay, Lawrence B. Schonberger, Martha L. Ospina, James J. Sejvar.

References

1. Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain-Barre syndrome. J Neuroimmunol. 1999; 100(1–2):74–87. http://www.ncbi.nlm.nih.gov/pubmed/10695718
2. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011; 36(2):123–33. https://doi.org/10.1159/000324710 PMID: 21422765

3. Salinas JL, Walteros DM, Styczynski A, Garzon F, Quijada H, Bravo E, et al. Zika virus disease-associated Guillain-Barre syndrome-Barranquilla, Colombia 2015–2016. J Neurol Sci. 2017; 381:272–7. https://doi.org/10.1016/j.jns.2017.09.001 PMID: 28991697

4. Styczynski AR, Malta J, Krow-Luca ER, Percio J, Nobrega ME, Vargas A, et al. Increased rates of Guillain-Barre syndrome associated with Zika virus outbreak in the Salvador metropolitan area, Brazil. PLoS Negl Trop Dis. 2017; 11(8):e0005869, https://doi.org/10.1371/journal.pntd.0005869 PMID: 28854206

5. Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhoomwegen J, et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016; 387(10027):1531–9. https://doi.org/10.1016/S0140-6736(16)00562-6 PMID: 26948433

6. Dirlikov E, Major CG, Medina NA, Lugo-Robles R, Matos D, Munoz-Jordan JL, et al. Clinical Features of Guillain-Barre Syndrome With vs Without Zika Virus Infection, Puerto Rico, 2016. JAMA Neurol. 2018; https://doi.org/10.1001/jamaneurol.2018.1058 PMID: 29799940

7. Munoz LS, Parra B, Pardo CA. Neurological Implications of Zika Virus Infection in Adults. J Infect Dis. 2017; 216(suppl_10):S897–s905. https://doi.org/10.1093/infdis/jix511 PMID: 29267923

8. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol. 2007; 6(7):589–94. https://doi.org/10.1016/S1474-4422(07)70130-8 PMID: 17537676

9. Mahecha MP, Ojeda E, Vega DA, Sarmiento-Monroy JC, Anaya JM. Guillain-Barre syndrome in Colombia: where do we stand now? Immunol Res. 2017; 65(1):72–81. https://doi.org/10.1007/s12026-016-8816-8 PMID: 27421717

10. Bernsen RA, de Jager AE, van der Meche FG, Suurmeijer TP. How Guillain-Barre patients experience their functioning after 1 year. Acta Neurol Scand. 2005; 112(1):51–6. https://doi.org/10.1111/j.1600-0404.2005.00429.x PMID: 15932357

11. Bersano A, Carpo M, Allaria S, Franciotta D, Citterio A, Nobile-Orazio E. Long term disability and social status change after Guillain-Barre syndrome. J Neurol. 2006; 253(2):214–8. https://doi.org/10.1007/s00415-005-0958-x PMID: 16096809

12. Soysal A, Aysal F, Caliskan B, Dogan Ak P, Mutluay B, Sakalli N, et al. Clinico-electrophysiological findings and prognosis of Guillain-Barre syndrome—10 years’ experience. Acta Neurol Scand. 2011; 123 (3):181–6. https://doi.org/10.1111/j.1600-0404.2010.01366.x PMID: 20497128

13. Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barre syndrome in south east England. J Neurol Neurosurg Psychiatry. 1998; 64(1):74–7. https://doi.org/10.1007/s12026-016-8816-8

14. Cheng Q, Jiang GX, Press R, Andersson M, Ekstedt B, Vrethem M, et al. Clinical epidemiology of Guillain-Barré syndrome in adults in Sweden 1996–97: a prospective study. Eur J Neurol. 2000; 7(6):685–92. http://www.ncbi.nlm.nih.gov/pubmed/11136356

15. Darweesh SK, Polinder S, Mulder MJ, Baena CP, van Leeuwen N, Franco OH, et al. Health-related quality of life in Guillain-Barré syndrome patients: a systematic review. J Peripher Nerv Syst. 2014; 19(1):24–35. https://doi.org/10.1111/jps.12051 PMID: 24456426

16. Merkies IS, Kieseier BC. Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Eur Neurol. 2016; 75(3–4):199–206. https://doi.org/10.1159/000453447 PMID: 27077919

17. Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011; 29(3):599–612. https://doi.org/10.1016/j.vaccine.2010.06.003 PMID: 2060491

18. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014; 137(Pt 1):33–43. https://doi.org/10.1093/brain/awt285 PMID: 24163275

19. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978; 2(8093):750–3. http://www.ncbi.nlm.nih.gov/pubmed/80682

20. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991; 54(12):1044–54. http://www.ncbi.nlm.nih.gov/pubmed/1783914

21. Zung WW, Richards OB, Short MJ. Self-rating depression scale in an outpatient clinic. Further validation of the SDS. Arch Gen Psychiatry. 1965; 13(6):508–15. http://www.ncbi.nlm.nih.gov/pubmed/4378854
22. Hennessy CH, Moriarty DG, Zack MM, Scherr PA, Brackbill R. Measuring health-related quality of life for public health surveillance. Public Health Rep. 1994; 109(5):665–72. http://www.ncbi.nlm.nih.gov/pubmed/7938388 PMID: 7938388

23. US Centers for Disease Control and Prevention. Measuring Healthy Days. Population Assessment of Health-Related Quality of Life. Atlanta, Georgia: CDC; 2000.

24. Merkies IS, Schmitz PI. Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients’ own clinical judgement in immune-mediated polyneuropathies. J Neurol Neurosurg Psychiatry. 2006; 77(8):970–2. https://doi.org/10.1136/jnnp.2005.076174 PMID: 16549419

25. Wei JC, Tsai WC, Citera G, Kotak S, Llamado L. Efficacy and safety of etanercept in patients from Latin America, Central Europe and Asia with early non-radiographic axial spondyloarthritis. International journal of rheumatic diseases. 2016; https://doi.org/10.1016/j.jrheum.2015.12.019 PMID: 27863065

26. Dirlikov E, Major CG, Mayshack M, Medina N, Matos D, Ryff KR, et al. Guillain-Barre Syndrome During Ongoing Zika Virus Transmission—Puerto Rico, January 1-July 31, 2016. MMWR Morb Mortal Wkly Rep. 2016; 65(34):910–4. https://doi.org/10.15585/mmwr.mm6534e1 PMID: 27584942

27. van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC. Mortality in Guillain-Barre syndrome. Neurology. 2013; 80(18):1650–4. https://doi.org/10.1212/WNL.0b013e3182904fcd PMID: 23576619

28. Dominguez-Moreno R, Tolosa-Tort P, Patino-Tamez A, Quintero-Bauman A, Collado-Frias DK, Miranda-Rodriguez MG, et al. [Mortality associated with a diagnosis of Guillain-Barre syndrome in adults of Mexican health institutions]. Rev Neurol. 2014; 58(1):4–10. http://www.ncbi.nlm.nih.gov/pubmed/24343535

29. Alshekhelee A, Hussain Z, Sultan B, Katirji B. Guillain-Barre syndrome: incidence and mortality rates in US hospitals. Neurology. 2008; 70(18):1608–13. https://doi.org/10.1212/01.wnl.0000310983.38724.d4 PMID: 18443311

30. Wong AH, Umapathi T, Shahrizaila N, Chan YC, Kokubun N, Fong MK, et al. The value of comparing mortality of Guillain-Barre syndrome across different regions. J Neurol Sci. 2014; 344(1–2):60–2. https://doi.org/10.1016/j.jns.2014.06.021 PMID: 24993467

31. Dimachkie MM, Barohn RJ. Guillain-barré syndrome. Curr Treat Options Neurol. 2013; 15(3):338–49. https://doi.org/10.1007/s11940-013-0231-z PMID: 23575768

32. Hughes RA, Comblath DR. Guillain-Barre syndrome. Lancet. 2005; 366(9497):1653–66. https://doi.org/10.1016/S0140-6736(05)67665-9 PMID: 16271648

33. Walling AD, Dickson G. Guillain-Barre syndrome. Am Fam Physician. 2013; 87(3):191–7. http://www.ncbi.nlm.nih.gov/pubmed/23418763

34. Comblath DR, Hughes RAC. Chapter 34 Guillain-Barré syndrome. In: Kimura J, editor. Handbook of Clinical Neurophysiology. 7: Elsevier; 2006. p. 695–707.

35. Fletcher DD, Lawn ND, Wolter TD, Wijdicks EF. Long-term outcome in patients with Guillain-Barre syndrome requiring mechanical ventilation. Neurology. 2000; 54(12):2311–5. http://www.ncbi.nlm.nih.gov/pubmed/10881259

36. Wang Y, Lang W, Zhang Y, Ma X, Zhou C, Zhang HL. Long-term prognosis of Guillain-Barre syndrome: evaluation of prognostic factors and clinical experience of automated double filtration plasmapheresis. J Clin Apher. 2003; 18(4):175–80. https://doi.org/10.1002/jca.10066 PMID: 14699593

37. Chang BC, Chang WN, Chen JB, Chee EC, Huang CR, Lu CH, et al. Long-term prognosis for Guillain-Barre syndrome: evaluation of prognostic factors and clinical experience of automated double filtration plasmapheresis. J Clin Apher. 2003; 18(4):175–80. https://doi.org/10.1002/jca.10066 PMID: 14699593

38. Gupta A, Taly AB, Srivastava K, Murali K, Cadena Bonfanti AA, Pacheco N, et al. Long-term clinical outcomes of Zika-associated Guillain-Barre syndrome. Emerg Microbes Infect. 2018; 7(1):148. https://doi.org/10.1038/s41426-018-0151-9 PMID: 30131486

39. Cheng BC, Chang WN, Chen JB, Chee EC, Huang CR, Lu CH, et al. Long-term prognosis for Guillain-Barre syndrome: evaluation of prognostic factors and clinical experience of automated double filtration plasmapheresis. J Clin Apher. 2003; 18(4):175–80. https://doi.org/10.1002/jca.10066 PMID: 14699593

40. Farbu E, Rudolph T, Stefansdottir S. Guillain Barre syndrome—Incidence and clinical course in Southern Rogaland, Norway. Clin Neurol Neurosurg. 2016; 141:33–7. https://doi.org/10.1016/j.clineuro.2015.12.008 PMID: 26724429

41. Centers for Disease Control and Prevention. Zika Virus Disease and Zika Virus Infection 2016 Case Definition, Approved June 2016 https://www.cdc.gov/nndss/conditions/zika/case-definition/2016/06/.